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PPeripheral Arterial Disease
Low Serum Testosterone and High
Serum Estradiol Associate With Lower
Extremity Peripheral Arterial Disease in Elderly Men
The MrOS Study in Sweden
Åsa Tivesten, MD, PHD,* Dan Mellström, MD, PHD,† Hans Jutberger, MD,†
Björn Fagerberg, MD, PHD,* Bodil Lernfelt, MD, PHD,† Eric Orwoll, MD, PHD,‡
Magnus K. Karlsson, MD, PHD,§ Östen Ljunggren, MD, PHD, Claes Ohlsson, MD, PHD†
Göteborg, Malmö, and Uppsala, Sweden; and Portland, Oregon
Objectives This study sought to determine whether serum levels of testosterone and estradiol associate with lower extrem-
ity peripheral arterial disease (PAD) in a large population-based cohort of elderly men.
Background Few studies have explored the relationship between serum sex steroids and lower extremity PAD in men.
Methods The Swedish arm of the MrOS (Osteoporotic Fractures in Men) study (n  3,014; average age 75.4 years) as-
sessed ankle-brachial index (ABI) and defined lower extremity PAD as ABI 0.90. Radioimmunoassay measured
serum levels of total testosterone, estradiol, and sex hormone-binding globulin, and we calculated free testoster-
one and free estradiol levels from the mass action equations.
Results A linear regression model including age, current smoking, previous smoking, diabetes, hypertension, body mass
index, free testosterone, and free estradiol showed that free testosterone independently and positively associ-
ates with ABI (p  0.001), whereas free estradiol independently and negatively associates with ABI (p  0.001).
Logistic regression analyses showed that free testosterone in the lowest quartile (vs. quartiles 2 to 4; odds ratio
[OR] 1.65, 95% confidence interval [CI] 1.22 to 2.23, p  0.001) and free estradiol in the highest quartile (vs.
quartiles 1 to 3; OR 1.45, 95% CI 1.09 to 1.94, p  0.012) independently associate with lower extremity PAD.
Conclusions This cross-sectional study shows for the first time that low serum testosterone and high serum estradiol levels
associate with lower extremity PAD in elderly men. Future prospective and interventional studies are needed to
establish possible causal relationships between sex steroids and the development of lower extremity PAD in
men. (J Am Coll Cardiol 2007;50:1070–6) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.088e
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mtherosclerosis is the major cause of lower extremity pe-
ipheral arterial disease (PAD), a disease increasingly rec-
gnized as a health burden worldwide (1). Concordant with
he systemic nature of atherosclerotic disease, lower extrem-
ty PAD and cardiovascular disease frequently occur to-
ether, and the risk factors for lower extremity PAD
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ccepted April 9, 2007.ssentially parallel those of coronary artery atherosclerosis
1,2). However, some differences exist (e.g., smoking is an
xceptionally powerful risk factor for lower extremity PAD,
nd hypertension is generally a weaker risk factor for lower
xtremity PAD than for coronary artery disease) (1,2).
See page 1077
Several lines of evidence support a role for sex hormones
n atherosclerotic disease in men. For example, several
tudies show an independent negative association between
erum testosterone and male carotid artery atherosclerosis as
ell as cardiovascular disease (3–6). In addition, we recently
etermined that circulating estradiol independently and
ositively predicts progression of carotid artery intima-
edia thickness in middle-aged men (7). Moreover, al-hough no current evidence suggests that testosterone treat-
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September 11, 2007:1070–6 Sex Hormones Associate With PAD in Menent affects the risk of cardiovascular disease (8), high-dose
strogen treatment of men with prostate cancer associates
ith increased cardiovascular morbidity and mortality (9).
Few large population-based association studies have ex-
mined the relationship between endogenous sex steroids
nd lower extremity PAD. Indeed, only 1 previous obser-
ational study, a small nested case-control study (40 male
ases and 41 control subjects) that determined no difference
n serum testosterone or estradiol levels between cases and
ontrol subjects (10), investigated the influence of sex
ormones on PAD in men.
We hypothesized that serum testosterone negatively and
erum estradiol positively associates with lower extremity
AD in men. The current study investigated a possible link
etween serum testosterone and estradiol levels and lower
xtremity PAD in a large population-based cohort of elderly
en.
ethods
tudy population. The MrOS (Osteoporotic Fractures in
en) study is a multicenter study including elderly men in
weden (n 3,014), Hong Kong (n 1,999), and the U.S.
n  5,995). The design of MrOS has been previously
escribed (11). In the Swedish arm of MrOS we investi-
ated possible links between sex steroid levels and ankle-
rachial index (ABI). With national population registers,
e randomly identified and enrolled men 69 to 80 years of
ge in 3 Swedish cities: Malmö, Uppsala, and Göteborg
n  1,000 in each city). Eligibility for study participation
equired the ability to walk unassisted; subjects with bilat-
ral hip prosthesis were excluded. There were no other
xclusion criteria. The MrOS study in Sweden was ap-
roved by the ethics committees at Göteborg, Lund, and
ppsala Universities. Informed consent was obtained from
ll study participants.
Both ABI and serum levels of all sex steroids (testoster-
ne, estradiol, and sex hormone-binding globulin [SHBG])
ere available for 2,812 subjects. After excluding 28 subjects
ith ABI 1.40 (see comment in following text), the
urrent analysis encompassed 2,784 subjects.
ssessment of covariates. A standardized questionnaire
11) collected information about present and previous
moking habits. Diabetes was defined as subjects’ report of
iabetes diagnosis by their doctors. Of subjects with self-
eported diagnosis of diabetes, 78% reported hypoglycemic
edication. Hypertension was defined as self-reported hy-
ertension diagnosis with either self-reported anti-
ypertensive treatment or systolic blood pressure 140 mm
g. Of subjects with self-reported diagnosis of hyperten-
ion, 90% reported antihypertensive medication. We used
tandard equipment to measure height and weight and
alculated body mass index (BMI) according to the formula
MI (kg/m2)  weight (kg)/height (m)2.
easurement of ABI. The ABI is a quick and noninvasive
easurement that provides objective information on the gresence and severity of lower
xtremity PAD. With a standard
ercury sphygmomanometer
nd a Doppler probe, we con-
ucted duplicate measures of su-
ine blood pressure in the right
rm and both ankles after sub-
ects rested in a quiet room for at
east 10 min. The study coordi-
ator placed appropriately sized
uffs over the right upper arm
nd around each ankle, proximal
o the malleolus, rapidly inflated
hem to 30 mm Hg above the
udible systolic pressure, and
hen slowly deflated them over
ach artery. A hand-held Dopp-
er (Huntleigh Mini Dopplex Model D900, Huntleigh
ealthcare AB, Limhamn, Sweden) recorded the pressure
n each artery as the first audible systolic pressure. After
erforming 2 measurements at each site, we used the mean
alue of systolic pressure taken first in the right brachial
rtery and then in the right and left posterior tibial artery.
e calculated ABI for each leg by dividing the posterior
ibial systolic pressure by the upper extremity pressure and
sed the lowest ABI to determine the extent of lower
xtremity PAD.
A low ABI indicates the presence of arterial disease in the
ower extremities. In accordance with the current standard,
e defined lower extremity PAD as ABI 0.90 (1,2,12), a
evel 95% sensitive and 99% specific for angiographically
iagnosed lower extremity PAD (12). Because ABI 1.40
ight represent falsely high values due to incompressible
rteries (12), we excluded 28 potential subjects with ABI
1.40 from our study.
An earlier study of 69-year-old men showed a linear
ssociation between ABI and intima-media thickness as
ell as the occurrence of atherosclerotic plaques in the
ommon femoral artery (13). Therefore, we considered ABI
s both a continuous and dichotomous variable (ABI less
han or exceeding 0.90).
ssessment of sex hormones. Ultrasensitive radioimmu-
oassay (RIA) (Orion Diagnostics, Esboo, Finland, limit of
etection 5 pmol/l [140 pg/dl], intra-assay coefficient of
ariation [CV] 3%, interassay CV 6%) measured total
stradiol, and an RIA (Orion Diagnostics, limit of detection
.1 nmol/l [3 ng/dl], intra-assay CV 6%, interassay CV 6%)
easured total testosterone. We used immunoradiometric
ssay (IRMA) (Orion Diagnostics, limit of detection 1.3
mol/l, intra-assay CV 3%, interassay CV 7%) to measure
HBG. Two subjects had undetectable estradiol levels and
had undetectable testosterone levels. Taking the concen-
rations of total testosterone, total estradiol, and SHBG into
ccount and assuming a fixed albumin concentration of 43
Abbreviations
and Acronyms
ABI  ankle-brachial index
BMI  body mass index
CI  confidence interval
CV  coefficient of
variation
IRMA  immunoradiometric
assay
OR  odds ratio
PAD  peripheral arterial
disease
RIA  radioimmunoassay
SHBG  sex hormone-
binding globulin/l, we calculated free testosterone and free estradiol accord-
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Sex Hormones Associate With PAD in Men September 11, 2007:1070–6ng to the method described by Vermeulen et al. (14) and
an den Beld et al. (15). We analyzed all samples in
uplicate in 1 laboratory and averaged the duplicates for
urther analyses.
tatistical analysis. Spearman rank correlation assessed
nivariate associations among variables. With linear regres-
ion equations, we adjusted the hormone–ABI relationships
Fig. 1) for selected covariates (the free estradiol–ABI
elationship was adjusted for free testosterone, and the free
estosterone–ABI relationship was adjusted for free estra-
iol). Analysis of variance followed by Tukey’s post hoc test
xamined differences in crude and adjusted ABI between
uartiles of sex hormone levels. We performed trend anal-
ses through linear regression analysis. Linear regression
nalysis with sex hormone levels divided into quartiles
etermined the independent predictors of ABI. Logistic
egression examined predictive values of low testosterone
lowest quartile vs. quartiles 2 to 4) and high estradiol
highest quartile vs. quartiles 1 to 3) for PAD (defined as
BI 0.9) (1,2,12) with and without adjustment for
ascular risk factors. Variables not normally distributed (i.e.,
MI and sex hormone levels) were log transformed under-
oing regression analyses. We performed statistical analyses
ith SPSS for Windows (version 13.0, SPSS, Chicago,
llinois).
Figure 1 Mean ABI According to Quartile of Serum Free Testos
Mean ankle-brachial index (ABI) (SE) according to quartile (Q) of serum free testo
tiles were as follows: Q1 0.003 to 0.23, Q2 0.23 to 0.30, Q3 0.30 to 0.39, and
1.60, Q3 1.60 to 2.12, and Q4 2.12 to 9.04 pmol/l. (C) Mean ABI (SE) adjuste
ABI (SE) adjusted for free testosterone according to quartile of serum free estra
Tukey=s post hoc test. *p  0.05 versus Q2, Q3, and Q4; #p  0.05 versus Q1 aesults
haracteristics of the study population. Table 1 shows
he characteristics of the study population, including serum
ex hormone levels. Among the 2,784 subjects, 213 (7.7%)
ad a self-reported history of prostate cancer. Exclusion of
hese subjects did not alter the results or conclusions of this
tudy.
erum testosterone associates positively and serum estra-
iol associates negatively with ABI. In univariate associ-
tion analyses, total and free testosterone correlated posi-
ively with ABI, and total and free estradiol correlated
egatively (Table 2). To further explore the relation be-
ween sex hormones and ABI, we plotted mean ABI against
uartiles of free testosterone and free estradiol (Figs. 1A and
B). Subjects within the lowest quartile of free testosterone
ad a lower mean ABI compared with subjects within
uartiles 2 to 4; subjects within the highest quartile of free
stradiol levels had a lower mean ABI compared with
uartiles 1 to 2. There was no linear association between
HBG and ABI (Table 2), and there was no evidence of a
hreshold effect in the relation between SHBG and ABI
ith SHBG quartiles (data not shown).
As previously described (16), serum levels of free testos-
erone and free estradiol clearly correlated positively (Pear-
on’s r 0.60, p 0.001). Therefore, we plotted mean ABI
e and Free Estradiol Levels
e (A) and free estradiol (B) levels. Limits in free testosterone for different quar-
9 to 1.43 nmol/l. Limits for free estradiol were Q1 0.05 to 1.20, Q2 1.20 to
ree estradiol according to quartile of serum free testosterone levels. (D) Mean
els. Statistical analyses were performed by analysis of variance followed by
.teron
steron
Q4 0.3
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September 11, 2007:1070–6 Sex Hormones Associate With PAD in Mendjusted for free estradiol against quartiles of free testoster-
ne (Fig. 1C) and mean ABI adjusted for free testosterone
gainst quartiles of free estradiol (Fig. 1D). Interestingly,
fter adjusting ABI for free testosterone levels, the negative
elation between quartiles of free estradiol and ABI ap-
eared more linear. Indeed, p values for linear trend across
uartiles 1 to 3 of free estradiol levels (not including quartile
in the analyses) were 0.37 before and 0.049 after adjusting
BI for free testosterone levels. In contrast, adjusting ABI
or free estradiol did not influence substantially the associ-
tion between ABI and quartile of free testosterone.
Because ABIs 1.30 to 1.40 might also reflect stiff arteries
1), the univariate relation between sex steroid levels and
BI was explored without this group (n  102), yielding
imilar results as if included (data not shown). Furthermore,
ex steroid levels did not differ in the 1.30 to 1.40 group as
ompared with a reference group within the MrOS Sweden
opulation (n  1,327) with normal ABIs of 1.10 to 1.29
12) (data not shown).
erum free testosterone independently and positively
ssociates with ABI, whereas free estradiol indepen-
ently and negatively associates with ABI. With linear
egression models including Swedish MrOS site, age, cur-
ent smoking, previous smoking, diabetes, hypertension,
haracteristics of the Study Population
Table 1 Characteristics of the Study Population
Factor
Prevalence or
Mean  SD
Age (yrs) 75.4 3.2
Smoking (%)
Never 35.2
Previous 56.2
Current 8.6
Body mass index (kg/m2) 26.4 3.5
Hypertension (%) 35.4
Diabetes (%) 9.3
ABI 1.08 0.17
PAD (ABI 0.9), % 10.9
Estradiol (pmol/l) 98.4 40.8
Free estradiol (pmol/l) 1.72 0.78
Testosterone (nmol/l) 16.9 7.0
Free testosterone (nmol/l) 0.31 0.14
SHBG (nmol/l) 43.2 21.9
 2,784.
ABI  ankle-brachial index; PAD  lower extremity peripheral arterial disease; SHBG  sex
ormone-binding globulin.
nivariate Associations Betweenerum Sex Hormone Levels and ABI
Table 2 Univariate Associations BetweenSerum Sex Hormone Levels and ABI
rs p Value
Estradiol 0.070 0.001
Free estradiol 0.061 0.001
Testosterone 0.051 0.008
Free testosterone 0.050 0.008
SHBG 0.013 0.51b
BI  ankle-brachial index; rs  Spearman rank correlation coefficient; SHBG  sex hormone-
inding globulin.MI, and quartile of free testosterone and free estradiol, we
xamined the likelihood that sex hormone levels and ABI
ssociate independently. Free testosterone independently
nd positively associates with ABI, and free estradiol inde-
endently and negatively associates with ABI (Table 3). As
xpected, age, smoking, diabetes, and hypertension nega-
ively associate with ABI (Table 3).
ow serum free testosterone and high free estradiol levels
ndependently associate with lower extremity PAD. We
ext evaluated the independent predictive values of low free
estosterone and high free estradiol for lower extremity
AD, defined as ABI 0.90 (1,2,12). Logistic regression
nalyses showed that serum levels of free testosterone in the
owest quartile as well as serum levels of free estradiol in the
ighest quartile associate with lower extremity PAD (Table
, Models 1 and 2). Further adjustment for smoking,
iabetes, hypertension, and BMI demonstrated that low
erum free testosterone and high serum free estradiol
ndependently associate with lower extremity PAD (Table
, Model 3). The corresponding odds ratios (ORs) of
ow/high total hormone levels for lower extremity PAD
ere included for reference. Although low free and total
estosterone yielded similar ORs for lower extremity PAD,
he relation for high total was weaker than for high free
stradiol.
Combining serum levels of free testosterone in the lowest
uartile with free estradiol in the highest quartile (n  69)
trongly associates with lower extremity PAD (model with
djustment for age and Swedish MrOS site: OR 3.72, 95%
onfidence interval [CI] 2.15 to 6.41, p  0.001; model
ith adjustment for age, Swedish MrOS site, smoking,
iabetes, hypertension, and BMI: OR 2.95, 95% CI 1.66 to
.24, p  0.001).
iscussion
ccumulating data support a role for sex hormones in
therosclerotic disease in men. However, the relationship
erum Free Testosterone Positively andndepend ntly Associates With ABI, and Estradiolgatively and Independently Associ tes With ABI
Table 3
Serum Free Testosterone Positively and
Independently Associates With ABI, and Estradiol
Negatively and Independently Associates With ABI
Standardized
Beta Coefficient p Value
Age 0.138 0.001
Current smoking 0.213 0.001
Previous smoking 0.125 0.001
Diabetes 0.055 0.004
Hypertension 0.125 0.001
Body mass index 0.008 0.68
Free testosterone 0.072 0.001
Free estradiol 0.080 0.001
ultiple linear regression analysis with ankle-brachial index (ABI) as the dependent variable and
ge, MrOS (Swedish Osteoporotic Fractures in Men) study site, current smoking, previous smoking,
iabetes, hypertension, body mass index, and quartiles of free testosterone and free estradiol as
ndependent variables.
ABI  ankle-brachial index.etween serum sex steroids and lower extremity PAD
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Sex Hormones Associate With PAD in Men September 11, 2007:1070–6equires further study. We show here that circulating free
estosterone positively associates with ABI in a large
opulation-based cohort of elderly men, indicating a nega-
ive association between testosterone and the degree of
therosclerotic disease in the lower extremities. In contrast,
ree estradiol negatively associates with ABI in the same
opulation, indicating that higher estradiol levels are asso-
iated with more atherosclerosis. Furthermore, when lower
xtremity PAD was defined as an ABI 0.90, we found
hat low serum testosterone (in the lowest quartile) and high
erum estradiol (in the highest quartile) associate with lower
xtremity PAD.
Few studies have examined endogenous estrogens and
AD in men (10), and the current study shows for the first
ime a positive association between serum estradiol levels
nd lower extremity PAD in men. Our data are in accor-
ance with accumulating evidence suggesting that endoge-
ous estrogens detrimentally affect atherosclerosis and car-
iovascular disease in men. For example, we recently found
hat circulating estradiol independently predicts the pro-
ression of carotid intima-media thickness in middle-aged
en (7). Furthermore, serum estradiol levels increased in
ubjects with coronary heart disease in a case-control study
f men in the Framingham cohort (17). In addition, another
tudy coupled the CC genotype of the estrogen receptor
lpha c.454-397TC polymorphism, possibly associated
ith enhanced receptor function (18), with increased inci-
ence of myocardial infarction in men (19,20).
The notion that endogenous estradiol detrimentally in-
uences atherosclerotic disease concurs with the association
etween high-dose estrogen treatment of men with prostate
ancer and increased cardiovascular morbidity and mortality
9). These studies employed various estrogen substances
ncluding parenterally administered estradiol (21,22). Addi-
ionally, the Coronary Drug Project showed excessive
eaths and recurrent infarction in men treated with conju-
ated equine estrogens after myocardial infarction (23).
urrently, no clinical trial has investigated the effect of
strogenic hormones on PAD in men (24). The adverse
ardiovascular effects of high-dose oral estrogen in men
ften have been ascribed to the prothrombotic effects of
ow Serum Free Testosterone as Well as High Free Estradiol Indep
Table 4 Low Serum Free Testosterone as Well as High Free Es
Model 1
(Adjusted for Age, MrOS Site)
OR (95% CI) p Value
Free testosterone (Q1 vs. Q2–4) 1.53 (1.18–1.98) 0.001
Total testosterone (Q1 vs. Q2–4) 1.75 (1.36–2.27) 0.001
Free estradiol (Q4 vs. Q1–3) 1.48 (1.13–1.93) 0.004
Total estradiol (Q4 vs. Q1–3) 1.38 (1.06–1.80) 0.017
ogistic regression analysis with lower extremity peripheral arterial disease (PAD) as the dependen
as adjusted for total estradiol; the model of free estradiol was adjusted for free testosterone; th
CI  confidence interval; OR  odds ratio; MrOS  Osteoporotic Fractures in Men study; Q  qstrogen (9,23). Our finding of a positive association be- sween serum estradiol levels and PAD supports the notion
hat estrogens, besides possibly increasing the risk for
hrombosis and thereby cardiovascular events, also influence
therogenesis in men.
Likewise, there are data in women supporting adverse
ffects of estrogens on atherosclerotic disease. In accordance
ith the results of the Coronary Drug Project (23), treat-
ent with conjugated equine estrogens increased the risk of
yocardial infarction and stroke in postmenopausal women
25,26). Furthermore, serum estradiol associates positively
ith atherosclerosis in postmenopausal women (27).
Thus, the results of the present as well as previous studies
hallenge the paradigm that estradiol protects against ath-
rosclerosis (28). The “estrogen protection hypothesis” is
upported by the beneficial effects of estrogens on, for
xample, serum lipids, vascular function, and experimental
therosclerosis in both genders (8,28). Furthermore, a
ecent population-based study suggested that endogenous
stradiol levels associate with lower risk for cardiovascular
vents in men (29). In postmenopausal women, treatment
ith estradiol slowed the progression of carotid intima-
edia thickness (30). Thus, opposing results suggesting
rotective as well as adverse effects of estradiol on athero-
clerotic disease are found in both genders and might not
nly be explained by differences between endogenous and
xogenous hormones. One might speculate that the effects
f estradiol on atherosclerosis might differ depending on
tage of the atherosclerotic process. In addition to species
ifferences, this might partly explain why the atheroprotec-
ive effects of estradiol on atherosclerosis in male mouse
odels are not repeated in men. Clearly, the impact of
stradiol on atherosclerotic disease in men (and women)
equires further examination.
The present study reports for the first time a negative
ssociation between serum testosterone levels and lower
xtremity PAD in men. This result is in agreement with
revious studies reporting a negative association between
erum testosterone levels and carotid intima-media thick-
ess (3 to 5) as well as cross-sectional studies showing a
onsistent inverse relationship between endogenous testos-
erone and male cardiovascular events (6). However, no
ntly Associate With Lower Extremity PAD
l Independently Associate With Lower Extremity PAD
Model 2
(Adjusted for Age, MrOS Site,
the Other Hormone*)
Model 3
(Adjusted for Age, MrOS Site,
the Other Hormone*, Body Mass
Index, Current Smoking, Previous
Smoking, Diabetes, Hypertension)
OR (95% CI) p Value OR (95% CI) p Value
1.78 (1.34–2.36) 0.001 1.65 (1.22–2.23) 0.001
1.94 (1.49–2.54) 0.001 1.70 (1.28–2.28) 0.001
1.61 (1.22–2.12) 0.001 1.45 (1.09–1.94) 0.012
1.48 (1.12–1.94) 0.005 1.33 (1.00–1.76) 0.052
le. *The model of free testosterone was adjusted for free estradiol; the model of total testosterone
l of total estradiol was adjusted for total testosterone.ende
tradio
t variabtudies have established a significant relationship between
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September 11, 2007:1070–6 Sex Hormones Associate With PAD in Menirculating testosterone and incident cardiovascular events
n men (6,8). In most animal studies, testosterone treatment
nhibits atherosclerosis in males; and testosterone (high-
ose) is a coronary vasodilator in men with established
therosclerosis (6). However, no current interventional
tudy has sufficient power to assess a possible protective
ffect of testosterone on human atherosclerosis or cardio-
ascular disease (6,24).
Interestingly, although serum testosterone and estradiol
ssociate positively, the relationship between testosterone
nd ABI contradicts the association between estradiol and
BI. In comparison, our previous data from the MrOS
weden cohort demonstrate that both testosterone and
stradiol associate positively with bone mineral density in
lderly men (16). Although earlier studies suggested that
estosterone confers protection against atherosclerosis
hrough local or systemic aromatization to estradiol
6,8,31), this notion is not supported by the present study,
emonstrating that free testosterone associated negatively
nd free estradiol associated positively with PAD. The more
recise role of testosterone and estradiol as well as their
recursors and derivatives in the human atherosclerotic
rocess requires future research.
Although low free and total testosterone yielded similar
Rs for lower extremity PAD, the relation was weaker for
igh total than for high free estradiol. This result is in
ccordance with previous results from this cohort on the
ssociation between total and free estradiol levels and bone
ineral density (16). Thus, it might be important to
alculate the bioactive estradiol concentration, which might
eflect the clinical situation more accurately than the total
ormone levels (15).
Limitations of the present study include its cross-
ectional design, which did not allow determination of the
emporal relationship between serum sex steroids and PAD.
hus, our results could reflect hormonal changes from the
AD disease process rather than vice versa. Furthermore,
ur results are limited to elderly Caucasian men. Because
he radioimmunoassay technique might result in artifacts at
he lowest estradiol levels, another possible limitation in-
olves the use of this assay for estradiol measurements (32).
ecause analyses were not adjusted for lipid disorders or
herapy for hyperlipidemia and confirmation of self-
eported diagnoses with medical records was not performed,
here is a possibility of residual confounding as a possible
xplanation for at least part of the observed associations.
he strengths of the present study include its population-
ased nature and the large number of men investigated.
onclusions
e show here that low serum testosterone and high serum
stradiol associate with lower extremity PAD in elderly
en. Future prospective and interventional studies areeeded to establish possible causal relationships between sexteroids and the development of lower extremity PAD in
en.
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